South Korean biosimilars developer Celltrion late yesterday announced new post-hoc analyses of its pivotal LIBERTY studies ...
Hosted on MSN3d
Celltrion announces 100 billion won share buybackCelltrion plans to buy back 100 billion won ($69 million) in stocks, purchasing 554,632 shares starting Thursday.
Celltrion announces 100 billion won share buyback, starts market purchase tomorrow Celltrion to start market share buyback ...
South Korea-based Celltrion today announced that the European Commission (EC) has granted marketing authorization for three ...
Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two ...
Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and subcutaneous (SC) formulation as a ...
Celltrion’s two biosimilar treatments for treating osteoporosis and preventing bone metastasis complications in cancer ...
South Koreas K. Pharma and Bio prepare for U.S. 25% pharmaceutical tariff U.S. pharmaceutical tariffs trigger strategic ...
Celltrion announced on Friday that it has received construction approval to build a new drug product (DP) manufacturing plant in Songdo, Incheon. The new facility, permitted by the Incheon Free ...
Celltrion expands its reach in Europe, securing marketing authorization from the European Commission (EC) for its denosumab biosimilar candidate (Stoboclo and Osenvelt) and its aflibercept biosimilar ...
Celltrion’s strategy with its biosimilar of MSD’s Remicade (infliximab), launched in most of Europe around two years ago, was to go for two marketing authorisations and sell rights to one of ...
In this part of his Pharmaceutical Executive video interview, Ian Chan, CEO of Abpro talks about how the recent NASDAQ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback